AMPHETAMINE SULFATE | A200166 | AZURITY PHARMACEUTICALS INC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition From Lachman Consultant Services Inc FDA-2014-P-1038 · 6 docket documents Lachman Consultant Services Inc, on behalf of a client, filed this petition pursuant to Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act requesting that the FDA determine that Amphetamine Sulfate Tablets, USP in strengths of 2.5 mg, 15 mg, 20 mg, and 30 mg are suitable for submission | Other | 2014-09-02 | Withdrawn | Lachman Consultant Services Inc |
Lachman Consultant Services, Inc. - Citizen Petition FDA-2009-P-0273 · 5 docket documents Lachman Consultant Services, Inc. filed this petition on behalf of a client requesting that the FDA determine whether Amphetamine Sulfate 5 mg and 10 mg Tablets (NDA 83-901 Products 001 and 002) held by Lannett Company, Inc. was voluntarily withdrawn or withheld from sale for reasons of safety or ef | 505(q) | 2009-06-18 | Open | — |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$0.4026
per ea
Lowest NADAC/Unit
$0.3780
per ea
Brand NDCs
0
Generic NDCs
2
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 52536005903AMPHETAMINE SULFATE 10 MG TAB | $0.4026 | EA | Generic | — | 2026-06-17 |
| 52536005703AMPHETAMINE SULFATE 5 MG TAB | $0.3780 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.